Cargando…
Rituximab-Related Late-Onset Neutropenia in Patients with Rheumatic Diseases: Successful Re-Challenge of the Treatment
Case series Patient: Female, 56 • Male, 64 Final Diagnosis: Neutropenia after Rituximab Symptoms: Cough • diarrhea • fever • headache Medication: Rituximab Clinical Procedure: — Specialty: Rheumatology OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: We describe here 2 patients who d...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407679/ https://www.ncbi.nlm.nih.gov/pubmed/25855510 http://dx.doi.org/10.12659/AJCR.892541 |
Sumario: | Case series Patient: Female, 56 • Male, 64 Final Diagnosis: Neutropenia after Rituximab Symptoms: Cough • diarrhea • fever • headache Medication: Rituximab Clinical Procedure: — Specialty: Rheumatology OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: We describe here 2 patients who developed late-onset neutropenia after Rituximab treatment. While this phenomenon is well described among patients suffering from hematological malignancies, such adverse effects are rare among patients with rheumatic diseases. CASE REPORT: Two patients, the first with rheumatoid arthritis and the second with granulomatosis with polyangiitis, were treated by Rituximab after all previous treatments failed. The patients developed late-onset neutropenia after several courses of treatment. The first patient, with symptomatic neutropenia, recovered after a single dose of granulocyte macrophage stimulating factor, and the second patient’s neutrophils increased spontaneously. Both patients were retreated by rituximab in their scheduled time without further complications. CONCLUSIONS: Our case series is unique because the same phenomenon appeared in patients with different rheumatic diseases. This case series confirms the possibility of continuing the treatment without further adverse effects. |
---|